Table 3 Associations between inpatient hospitalization risk and nintedanib adherence trajectory

Time to first all-cause inpatient hospital event

 Unadjusted hazard ratio (95% CI)

ref

1.11 (0.80, 1.53)

1.53 (1.13, 2.07)

1.52 (1.16, 2.00)

1.42 (1.10, 1.83)

  P-value

0.54

0.006

0.003

0.007

 Adjusted hazard ratio (95% CI)

ref

1.12 (0.80, 1.56)

1.54 (1.12, 2.11)

1.46 (1.09, 1.94)

1.34 (1.03, 1.75)

  P-value

0.51

0.008

0.01

0.03

Time to first IPF-related inpatient hospital event

 Unadjusted hazard ratio (95% CI)

ref

1.07 (0.67, 1.70)

1.85 (1.26, 2.73)

1.31 (0.88, 1.94)

1.16 (0.81, 1.67)

  P-value

0.78

0.002

0.18

0.42

 Adjusted hazard ratio (95% CI)

ref

1.12 (0.70, 1.78)

1.84 (1.24, 2.72)

1.26 (0.84, 1.91)

1.08 (0.75, 1.57)

  P-value

0.64

0.002

0.27

0.67

Sample size, n (%)

781 (43.4)

202 (11.2)

190 (10.6)

255 (14.2)

370 (20.6)